24 Feb 2016 12:39
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company")
Result of AGM
Redx, the drug discovery and development company, announces that all resolutions at the Group's Annual General Meeting, held today, were duly passed.
For further information, please contact:
Redx Pharma Plc | T: 0151 706 4747 |
Neil Murray, Chief Executive Company website: redxpharma.com |
|
|
|
Shore Capital (Nomad and Broker) | T: 020 7408 4090 |
Bidhi Bhoma/ Edward Mansfield/ Patrick Castle |
|
|
|
KTZ Communications | T: 020 3178 6378 |
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson |
|
About Redx Pharma Plc
www.redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.